ABSTRACT
HER-2 is a biomarker participating in tumor cells biology that has been thoroughly studied in breast cancer, but it can also be overexpressed in other neoplasms like gastric cancer. In this setting there are more reported cases about HER-2 positive immunohistochemistry in intestinal subtype than in diffuse subtype; in those cases, staining is limited to basolateral membrane. Positivity may be verified through fluorescent hybridization. This case is about a 30-year-old man diagnosed with diffuse gastric carcinoma from a total gastrectomy surgical specimen, in which 3+ HER-2 immunohistochemistry is confirmed in the totality of the plasma membrane of mucosa cells and is sustained using fluorescent hybridization for HER-2.
HER-2 es un biomarcador que colabora con la biología de la célula tumoral y ha sido ampliamente estudiado en cáncer de mama, pero también puedesobreexpresarse en otras neoplasias como el cáncer gástrico. En este escenario se reportan más casos deinmunohistoquímica positiva por HER-2 en el subtipo intestinal con respecto al subtipo difuso; en dichos casos, la tinción se limita a la membrana basolateral. Los casos positivos pueden ser verificados a través de hibridación fluorescente in situ. Se presenta el casode un sujeto masculino de 30 años con diagnóstico de carcinoma gástrico difuso a través de un espécimenquirúrgico de gastrectomía total, a la cual se le confirma mediante inmunohistoquímica 3+ para HER-2 enla totalidad de la membrana celular de las células de la mucosa y corroborado utilizando la técnica hibridaciónfluorescente in situ para HER-2.
Subject(s)
Humans , Male , Adult , Adenocarcinoma/diagnosis , Stomach Neoplasms/diagnosis , /metabolism , Adenocarcinoma/metabolism , Immunohistochemistry , In Situ Hybridization, Fluorescence , Biomarkers, Tumor , Stomach Neoplasms/metabolismABSTRACT
Background: Mortality caused by cardial gastric cancer in Chile, is increasing. Previously we demonstrated an association between Epstein Barr virus and this specific location of gastric cancer. Aim: To perform a clinical and molecular characterization of cardial gastric cancer associated to Epstein Barr virus. Material and methods: Epstein Barr virus was identified in 93 cardial gastric tumors, by in situ hybridization. Clinical and pathological features, survival and expression of p53 and c-erbB2 were compared between tumors with or without the presence of the virus. Results: Twenty two (23.6%) tumors expressed Epstein Barr virus. No difference in sex or age of patients with tumors positive or negative for the virus was observed. Epstein Barr positive tumors had a tendency to have a higher frequency of Bormann III endoscopic appearance and a lower frequency of p53 accumulation (p=0.06). Five years survival was 67% and 42% of tumors positive and negative for the presence of the virus, respectively (p=0.57). Conclusions: Our results, although not significant, show a tendency towards unique characteristics of cardial gastric tumors associated to Epstein Barr virus.